Decisions Home

United States Cancer Biological Market Insight

Published: 18 June 2026   |   Report Format: Electronic (PDF)

United States Cancer Biological Market is projected to grow at a CAGR of around 10.8%, driven by rising cancer prevalence, increasing adoption of immunotherapies and targeted biologics, expanding biologics pipelines, and continuous advancements in precision oncology treatments

United States Cancer Biological Market Forecasts to 2035

  • The United States Cancer Biological Market Size Was Estimated at USD 58.7 Billion in 2025.
  • The Market Size is Expected to Grow at a CAGR of around 10.8% from 2025 to 2035.
  • The United States Cancer Biological Market Size is Expected to Reach around USD 163.8 Billion by 2035.

 

Notable Insights for the United States Cancer Biological Market

  • Segmentation Based on Product Type, Monoclonal Antibodies held a dominant position in 2025 with nearly 47% share, supported by their broad clinical application and strong adoption across multiple cancer indications.
  • Segmentation Based on Cancer Type, the Lung Cancer Segment accounted for approximately 24% share in 2025, driven by increasing incidence rates and expanding approvals for immuno-oncology biologics.
  • The market is led by Merck & Co., Inc. and Bristol Myers Squibb Company; Merck reported approximately USD 64.2 billion revenue in FY2025, reflecting its leadership in oncology biologics and immunotherapy portfolios.
  • Pfizer Inc. generated approximately USD 63.6 billion revenue in FY2025, while Roche Holding AG reported nearly USD 72.4 billion revenue, highlighting the financial strength of leading cancer biologics manufacturers.

Download the eBook (ToC)

We value your privacy.

🔒 Insight Sample

Research Methodologies Used to Analyze the United States Cancer Biological Market

This study employs a combination of primary and secondary research methodologies to analyze the United States Cancer Biological Market. Primary research includes interviews and discussions with biologics manufacturers, oncologists, cancer researchers, hospital procurement specialists, distributors, regulatory authorities, healthcare providers, and industry stakeholders. Secondary research involves company annual reports, investor presentations, FDA publications, cancer association reports, scientific journals, white papers, and proprietary databases. Market estimations are derived using both top-down and bottom-up approaches, while data triangulation and validation techniques ensure the accuracy and reliability of market forecasts, competitive assessments, and industry trends.

 

Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making

What is Decisions Advisors Research?

Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United States cancer biological market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

Top Companies in United States Cancer Biological Market

 

Recent Developments:

 

Market Segmentation:

United States Cancer Biological Market, By Product Type

 

United States Cancer Biological Market, By Cancer Type

 

United States Cancer Biological Market, By Mechanism of Action

 

United States Cancer Biological Market, By End User

 

United States Cancer Biological Market, By Distribution Channel

 

Expert Views:

The United States Cancer Biological Market is expected to witness substantial growth through 2035, supported by increasing demand for precision oncology, expanding biologics approvals, rising investment in cancer research, and continued product launches and strategic collaborations among leading market participants.

Author: Komal and Radhika By Decisions Advisors and Consulting

Related Insights

United States Blood Group Market Size is Expected to Reach around USD 3.73 Billion by 2035 | CAGR of 7.2%

Jun 2026

Canada Microscope Market Size to Grow USD 1293.2 Million by 2035 | CAGR of 8.34% Market Report Till 2035

May 2026

Japan Biopharmaceutical Courier Market Size to Grow USD 574.6 Million by 2035 | CAGR of 6.28%

Jun 2026